Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
Follow-Up Questions
Qui est le CEO de Vicapsys Life Sciences Inc ?
Mr. Federico Pier est le Chief Executive Officer de Vicapsys Life Sciences Inc, il a rejoint l'entreprise depuis 2019.
Quelle est la performance du prix de l'action VICP ?
Le prix actuel de VICP est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Vicapsys Life Sciences Inc ?
Vicapsys Life Sciences Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Vicapsys Life Sciences Inc ?
La capitalisation boursière actuelle de Vicapsys Life Sciences Inc est de $0
